
US-based Parion Sciences is committed to pioneering research and development in healthcare.
Founded in Durham, United States, Parion Sciences is a development stage company focused on pioneering research and development in healthcare. The company's core mission is to restore the innate mucosal surface defense of the lung through innovative therapies. Parion's product pipeline includes ENaC pulmonary treatments, tPAD, and mucolytic agents, all targeting respiratory diseases caused by defective mucosal host defense mechanisms.
Parion Sciences has established notable partnerships and affiliations with leading research institutions and pharmaceutical companies. The company has achieved significant milestones in advancing its clinical trials and developing its therapeutic technologies. With a strong focus on respiratory health, Parion Sciences has made a substantial impact in the field of mucosal defense, contributing to improved treatment options for patients with chronic respiratory conditions.

Pulmatrix
pulmatrix.com

Paratus Sciences

Pulmokine
pulmokine.net

Inception Sciences

PulmonIx
pulmonix.com

Parimer Scientific
parimer.com

Parallax Health Sciences

Spyryx Biosciences

Pneuma Respiratory
Lung Biotechnology
unither.com

Parthenon Therapeutics
parthenontx.com

Mucommune
mucommune.com

Path BioAnalytics

Entrinsic Bioscience

Synedgen
synedgen.com
Companies similar to Parion Sciences include Pulmatrix, Paratus Sciences, Pulmokine and Inception Sciences.
Parion Sciences was founded in 1999.
Parion Sciences' headquarters is located in Durham, NC, US.
Parion Sciences' most recent funding round was for $3M (USD) in September 2014.
As of Sep 16, 2014, Parion Sciences has raised a total of $3M (USD).
Parion Sciences has 10 employees as of Feb 5, 2024.